<DOC>
	<DOCNO>NCT01264770</DOCNO>
	<brief_summary>The purpose study evaluate improvement sign symptom rheumatoid arthritis ( RA ) fostamatinib compare placebo adalimumab patient Disease-Modifying anti-rheumatic drug ( DMARD ) na√Øve , DMARD intolerant inadequate response DMARDs . The study last approximately six month</brief_summary>
	<brief_title>Evaluation Efficacy Safety Fostamatinib Monotherapy Compared With Adalimumab Monotherapy Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Sub-study : Full title : Optional Genetic Research Date : 10 September 2010 Version : 1 Objectives : To collect store , appropriate consent , DNA sample future exploratory research genes/genetic variation may influence response ( ie , absorption , distribution , metabolism excretion , safety , tolerability efficacy ) fostamatinib disodium and/or adalimumab ; and/or susceptibility , progression prognosis RA The main study recruitment complete , sub study recruitment continue target reach , estimate June 2013 Sub-study : Full title : ( Sub-study OSKIRA-4 ) : A Phase IIB , Multi-Centre , Randomised , Double-Blind , Placebo-Controlled , Parallel Group Study Efficacy Safety Fostamatinib Disodium Monotherapy Compared Placebo Adalimumab Monotherapy Patients Active Rheumatoid Arthritis : Magnetic Resonance Imaging Sub-Study Date : 21 March 2011 Version : 1 Primary objective : Assess efficacy fostamatinib reduce joint synovial disease activity measure : - Change baseline Week 6 ( versus placebo ) OMERACT RAMRIS synovitis score .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female age 18 Active rheumatoid arthritis ( RA ) diagnose age 16 diagnosis within 5 year prior study visit 1 inadequate response treatment maximum 2 DiseaseModifying antirheumatic drug ( DMARD ) therapy , diagnosis within 5 year prior study visit 1 intolerance DMARD therapy , diagnosis within 2 year prior study visit 1 previous use DMARDs 4 swollen joint 4 tender/painful joint ( 28 joint count ) either Erythrocyte Sedimentation Rate ( ESR ) blood result 28mm/h , CReactive Protein ( CRP ) blood result 10mg/L At least 2 follow : documented history current presence positive rheumatoid factor ( blood test ) , radiographic erosion within 12 month prior study enrolment , presence serum anticyclic citrullinated peptide antibody ( blood test ) Females pregnant breast feed Poorly control hypertension Liver disease significant liver function test abnormality Certain inflammatory condition ( rheumatoid arthritis ) , connective tissue diseases chronic pain disorder Recent significant cardiovascular disease Significant active recent infection include tuberculosis Previously receive treatment TNF alpha antagonist ( include etanercept , certolizumab , adalimumab , infliximab , golimumab ) anakinra previous treatment biological agent include rituximab , abatacept tocilizumab Use DMARDs within 6 week first study visit Severe renal impairment Neutropenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>OSKIRA</keyword>
	<keyword>fostamatinib</keyword>
</DOC>